FDA批准利用供體免疫細胞預防血液癌症患者嚴重併發症的新療法
.gov 表示它是官方網站。聯邦政府網站通常以 .gov 或 .mil 結尾。在分享敏感資訊之前，請確保您造訪的是聯邦政府網站。網站是安全的。
正文內容
Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
常見問題
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
